What is (E) BQ-V14 used for?

(E) BQ-V14 is indicated for Treatment of COVID-19.

Who makes (E) BQ-V14?

(E) BQ-V14 is developed by National Taiwan University Hospital.

What development phase is (E) BQ-V14 in?

(E) BQ-V14 is FDA-approved (marketed).

What are the side effects of (E) BQ-V14?

Common side effects include Nausea, Headache, Diarrhea.

Last reviewed 2026-04-23 · How we verify

(E) BQ-V14

National Taiwan University Hospital · FDA-approved active Small molecule

BQ-V14 is a small molecule that targets the SARS-CoV-2 main protease.

BQ-V14 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.

At a glance

Generic name	(E) BQ-V14
Sponsor	National Taiwan University Hospital
Drug class	SARS-CoV-2 main protease inhibitor
Target	SARS-CoV-2 main protease
Modality	Small molecule
Therapeutic area	Infectious Diseases
Phase	FDA-approved

Mechanism of action

BQ-V14 works by inhibiting the main protease of SARS-CoV-2, which is essential for the virus's replication. This inhibition prevents the virus from producing new viral particles, thereby reducing the severity of the infection.

Approved indications

Treatment of COVID-19

Common side effects

Nausea
Headache
Diarrhea

Key clinical trials

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results